Abstract
The article presents current data on algorithms for managing patients with the most common forms of spondylarthritis — ankylosing spondylitis, axial spondylarthritis and psoriatic arthritis, based on existing national and European recommendations. The analysis of innovative approaches to the patho‑genetic therapy of spondyloarthritis with special attention to the inhibition of interleukin‑17 using the drug secukinumab. Along with the literature data, there is a clinical experience of using secukinumab in patients with ankylosing spondylitis, axial spondyloarthritis, and psoriatic arthritis. It has been shown that secukinumab can improve the quality of treatment and achieve clinical remission in patients with high disease activity and adverse prognostic factors. In connection with the high efficacy and safety of treatment, the feasibility of using secukinumab as a first‑line biological agent with insufficient response to a standard basic drug is discussed.
Highlights
there is a clinical experience of using secukinumab in patients
It has been shown that secukinumab can improve the quality of treatment
Поражение кожи, глаз (передний увеит); и без признаков сакроилиита (нерентгенологический СпА)
Summary
Наличие тканевого антигена HLA-B 27 (+); в рубрике «Спондилопатии» (шифр М45 — М49), — Сакроилиит — воспаление подвздошно-крестцовых это группа генетически связанных заболеваний с общими сочленений. Клиническими чертами и их перекрестом между нозо‐
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have